Tanox, Sunol deal

TNOX agreed to acquire Sunol's tissue factor antagonist program to treat inflammatory diseases and cancer for stock and cash. TNOX will issue 800,000 shares and pay $6 million to Sunol. Based on TNOX's close of $10.33 on March 24, the last trading day before the deal was announced. The deal is valued at $14.3 million. ...